nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—DDC—telencephalic ventricle—brain cancer	0.0597	0.135	CbGeAlD
Methyldopa—DDC—pineal body—brain cancer	0.0518	0.117	CbGeAlD
Methyldopa—COMT—telencephalic ventricle—brain cancer	0.0395	0.0894	CbGeAlD
Methyldopa—DDC—ganglion—brain cancer	0.0371	0.0842	CbGeAlD
Methyldopa—DDC—hindbrain—brain cancer	0.0282	0.0638	CbGeAlD
Methyldopa—COMT—ganglion—brain cancer	0.0246	0.0557	CbGeAlD
Methyldopa—Pericarditis—Procarbazine—brain cancer	0.0228	0.042	CcSEcCtD
Methyldopa—DDC—brainstem—brain cancer	0.0161	0.0366	CbGeAlD
Methyldopa—VIIth nerve paralysis—Carmustine—brain cancer	0.0151	0.0277	CcSEcCtD
Methyldopa—DDC—telencephalon—brain cancer	0.0143	0.0325	CbGeAlD
Methyldopa—Bone marrow depression—Hydroxyurea—brain cancer	0.0113	0.0208	CcSEcCtD
Methyldopa—Amenorrhoea—Procarbazine—brain cancer	0.0112	0.0207	CcSEcCtD
Methyldopa—COMT—brainstem—brain cancer	0.0107	0.0242	CbGeAlD
Methyldopa—DDC—midbrain—brain cancer	0.0103	0.0233	CbGeAlD
Methyldopa—Nightmare—Procarbazine—brain cancer	0.00954	0.0176	CcSEcCtD
Methyldopa—COMT—telencephalon—brain cancer	0.00948	0.0215	CbGeAlD
Methyldopa—Pancytopenia—Lomustine—brain cancer	0.00927	0.0171	CcSEcCtD
Methyldopa—DDC—endocrine gland—brain cancer	0.00904	0.0205	CbGeAlD
Methyldopa—DDC—head—brain cancer	0.00892	0.0202	CbGeAlD
Methyldopa—Gynaecomastia—Procarbazine—brain cancer	0.00884	0.0163	CcSEcCtD
Methyldopa—Tenderness—Hydroxyurea—brain cancer	0.00876	0.0161	CcSEcCtD
Methyldopa—Amenorrhoea—Hydroxyurea—brain cancer	0.0087	0.016	CcSEcCtD
Methyldopa—DDC—central nervous system—brain cancer	0.00814	0.0185	CbGeAlD
Methyldopa—Haemolytic anaemia—Procarbazine—brain cancer	0.00794	0.0146	CcSEcCtD
Methyldopa—COMT—gonad—brain cancer	0.00791	0.0179	CbGeAlD
Methyldopa—COMT—pituitary gland—brain cancer	0.00772	0.0175	CbGeAlD
Methyldopa—COMT—medulla oblongata—brain cancer	0.00745	0.0169	CbGeAlD
Methyldopa—Endocrine disorder—Temozolomide—brain cancer	0.0072	0.0133	CcSEcCtD
Methyldopa—Liver injury—Temozolomide—brain cancer	0.0071	0.0131	CcSEcCtD
Methyldopa—COMT—midbrain—brain cancer	0.0068	0.0154	CbGeAlD
Methyldopa—Amenorrhoea—Temozolomide—brain cancer	0.0068	0.0125	CcSEcCtD
Methyldopa—SLC15A1—endocrine gland—brain cancer	0.00672	0.0152	CbGeAlD
Methyldopa—COMT—spinal cord—brain cancer	0.00664	0.015	CbGeAlD
Methyldopa—DDC—brain—brain cancer	0.00647	0.0147	CbGeAlD
Methyldopa—Toxic epidermal necrolysis—Procarbazine—brain cancer	0.00646	0.0119	CcSEcCtD
Methyldopa—Infection—Carboplatin—brain cancer	0.0063	0.0116	CcSEcCtD
Methyldopa—Eosinophilia—Procarbazine—brain cancer	0.00614	0.0113	CcSEcCtD
Methyldopa—Leukopenia—Lomustine—brain cancer	0.00609	0.0112	CcSEcCtD
Methyldopa—Pancreatitis—Procarbazine—brain cancer	0.00608	0.0112	CcSEcCtD
Methyldopa—Angina pectoris—Procarbazine—brain cancer	0.00604	0.0111	CcSEcCtD
Methyldopa—COMT—endocrine gland—brain cancer	0.00598	0.0135	CbGeAlD
Methyldopa—COMT—head—brain cancer	0.0059	0.0134	CbGeAlD
Methyldopa—Pancytopenia—Procarbazine—brain cancer	0.00589	0.0108	CcSEcCtD
Methyldopa—Gynaecomastia—Carmustine—brain cancer	0.00553	0.0102	CcSEcCtD
Methyldopa—Infection—Lomustine—brain cancer	0.00551	0.0101	CcSEcCtD
Methyldopa—Thrombocytopenia—Lomustine—brain cancer	0.00543	0.01	CcSEcCtD
Methyldopa—Jaundice—Procarbazine—brain cancer	0.00539	0.00991	CcSEcCtD
Methyldopa—COMT—central nervous system—brain cancer	0.00539	0.0122	CbGeAlD
Methyldopa—COMT—cerebellum—brain cancer	0.00526	0.0119	CbGeAlD
Methyldopa—Body temperature increased—Carboplatin—brain cancer	0.00502	0.00923	CcSEcCtD
Methyldopa—Breast disorder—Hydroxyurea—brain cancer	0.00501	0.00923	CcSEcCtD
Methyldopa—ADRA2A—telencephalon—brain cancer	0.00483	0.0109	CbGeAlD
Methyldopa—Nasal congestion—Temozolomide—brain cancer	0.00476	0.00876	CcSEcCtD
Methyldopa—Pancreatitis—Hydroxyurea—brain cancer	0.0047	0.00865	CcSEcCtD
Methyldopa—Pancytopenia—Hydroxyurea—brain cancer	0.00455	0.00838	CcSEcCtD
Methyldopa—Body temperature increased—Lomustine—brain cancer	0.00439	0.00808	CcSEcCtD
Methyldopa—Weight increased—Hydroxyurea—brain cancer	0.00436	0.00803	CcSEcCtD
Methyldopa—Infestation—Hydroxyurea—brain cancer	0.00428	0.00787	CcSEcCtD
Methyldopa—Infestation NOS—Hydroxyurea—brain cancer	0.00428	0.00787	CcSEcCtD
Methyldopa—COMT—brain—brain cancer	0.00428	0.00969	CbGeAlD
Methyldopa—Liver function test abnormal—Carmustine—brain cancer	0.00414	0.00762	CcSEcCtD
Methyldopa—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00404	0.00744	CcSEcCtD
Methyldopa—ADRA2A—gonad—brain cancer	0.00403	0.00912	CbGeAlD
Methyldopa—ADRA2A—pituitary gland—brain cancer	0.00393	0.0089	CbGeAlD
Methyldopa—Breast disorder—Temozolomide—brain cancer	0.00392	0.00721	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.0039	0.00718	CcSEcCtD
Methyldopa—Leukopenia—Procarbazine—brain cancer	0.00387	0.00711	CcSEcCtD
Methyldopa—Cardiac failure congestive—Etoposide—brain cancer	0.00383	0.00704	CcSEcCtD
Methyldopa—ADRA2A—medulla oblongata—brain cancer	0.00379	0.00859	CbGeAlD
Methyldopa—Abdominal distension—Temozolomide—brain cancer	0.00377	0.00694	CcSEcCtD
Methyldopa—Pancytopenia—Carmustine—brain cancer	0.00368	0.00678	CcSEcCtD
Methyldopa—Arthralgia—Procarbazine—brain cancer	0.00368	0.00677	CcSEcCtD
Methyldopa—Myalgia—Procarbazine—brain cancer	0.00368	0.00677	CcSEcCtD
Methyldopa—Pancytopenia—Temozolomide—brain cancer	0.00356	0.00655	CcSEcCtD
Methyldopa—Vomiting—Lomustine—brain cancer	0.00353	0.0065	CcSEcCtD
Methyldopa—Oedema—Procarbazine—brain cancer	0.00352	0.00649	CcSEcCtD
Methyldopa—Infection—Procarbazine—brain cancer	0.0035	0.00644	CcSEcCtD
Methyldopa—Angiopathy—Hydroxyurea—brain cancer	0.00348	0.00641	CcSEcCtD
Methyldopa—ADRA2A—midbrain—brain cancer	0.00347	0.00785	CbGeAlD
Methyldopa—Erectile dysfunction—Temozolomide—brain cancer	0.00345	0.00635	CcSEcCtD
Methyldopa—Thrombocytopenia—Procarbazine—brain cancer	0.00345	0.00635	CcSEcCtD
Methyldopa—Weight increased—Temozolomide—brain cancer	0.00341	0.00628	CcSEcCtD
Methyldopa—ADRA2A—spinal cord—brain cancer	0.00338	0.00766	CbGeAlD
Methyldopa—Infestation NOS—Temozolomide—brain cancer	0.00334	0.00615	CcSEcCtD
Methyldopa—Infestation—Temozolomide—brain cancer	0.00334	0.00615	CcSEcCtD
Methyldopa—Nausea—Lomustine—brain cancer	0.0033	0.00607	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00321	0.00591	CcSEcCtD
Methyldopa—Paraesthesia—Procarbazine—brain cancer	0.00316	0.00582	CcSEcCtD
Methyldopa—Hepatobiliary disease—Temozolomide—brain cancer	0.00316	0.00582	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Etoposide—brain cancer	0.00312	0.00575	CcSEcCtD
Methyldopa—Connective tissue disorder—Carmustine—brain cancer	0.00305	0.00561	CcSEcCtD
Methyldopa—ADRA2A—endocrine gland—brain cancer	0.00304	0.0069	CbGeAlD
Methyldopa—Constipation—Procarbazine—brain cancer	0.00301	0.00555	CcSEcCtD
Methyldopa—ADRA2A—head—brain cancer	0.003	0.00681	CbGeAlD
Methyldopa—Hepatitis—Temozolomide—brain cancer	0.003	0.00552	CcSEcCtD
Methyldopa—Leukopenia—Hydroxyurea—brain cancer	0.00299	0.00551	CcSEcCtD
Methyldopa—Connective tissue disorder—Temozolomide—brain cancer	0.00295	0.00542	CcSEcCtD
Methyldopa—Pancytopenia—Etoposide—brain cancer	0.00285	0.00524	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00283	0.0052	CcSEcCtD
Methyldopa—Body temperature increased—Procarbazine—brain cancer	0.00279	0.00513	CcSEcCtD
Methyldopa—Cardiac disorder—Temozolomide—brain cancer	0.00278	0.00512	CcSEcCtD
Methyldopa—ADRA2A—central nervous system—brain cancer	0.00274	0.00621	CbGeAlD
Methyldopa—Oedema—Hydroxyurea—brain cancer	0.00273	0.00502	CcSEcCtD
Methyldopa—Angiopathy—Temozolomide—brain cancer	0.00272	0.00501	CcSEcCtD
Methyldopa—Mental disorder—Carmustine—brain cancer	0.00272	0.005	CcSEcCtD
Methyldopa—Infection—Hydroxyurea—brain cancer	0.00271	0.00499	CcSEcCtD
Methyldopa—Mediastinal disorder—Temozolomide—brain cancer	0.0027	0.00497	CcSEcCtD
Methyldopa—ADRA2A—cerebellum—brain cancer	0.00268	0.00607	CbGeAlD
Methyldopa—Nervous system disorder—Hydroxyurea—brain cancer	0.00267	0.00492	CcSEcCtD
Methyldopa—Infestation NOS—Etoposide—brain cancer	0.00267	0.00492	CcSEcCtD
Methyldopa—Infestation—Etoposide—brain cancer	0.00267	0.00492	CcSEcCtD
Methyldopa—Thrombocytopenia—Hydroxyurea—brain cancer	0.00267	0.00491	CcSEcCtD
Methyldopa—Skin disorder—Hydroxyurea—brain cancer	0.00265	0.00488	CcSEcCtD
Methyldopa—Mental disorder—Temozolomide—brain cancer	0.00263	0.00484	CcSEcCtD
Methyldopa—Jaundice—Etoposide—brain cancer	0.00261	0.0048	CcSEcCtD
Methyldopa—Hypersensitivity—Procarbazine—brain cancer	0.0026	0.00478	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—OTX2—brain cancer	0.00255	0.245	CbGpPWpGaD
Methyldopa—Asthenia—Procarbazine—brain cancer	0.00253	0.00465	CcSEcCtD
Methyldopa—Hepatobiliary disease—Etoposide—brain cancer	0.00253	0.00465	CcSEcCtD
Methyldopa—Agranulocytosis—Etoposide—brain cancer	0.00249	0.00459	CcSEcCtD
Methyldopa—Dopamine—CYP2C9—brain cancer	0.00246	0.506	CrCbGaD
Methyldopa—Leukopenia—Carmustine—brain cancer	0.00242	0.00445	CcSEcCtD
Methyldopa—Diarrhoea—Procarbazine—brain cancer	0.00241	0.00444	CcSEcCtD
Methyldopa—Epinephrine—CYP2C9—brain cancer	0.0024	0.494	CrCbGaD
Methyldopa—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00235	0.00433	CcSEcCtD
Methyldopa—Leukopenia—Temozolomide—brain cancer	0.00234	0.0043	CcSEcCtD
Methyldopa—Constipation—Hydroxyurea—brain cancer	0.00233	0.00429	CcSEcCtD
Methyldopa—Dizziness—Procarbazine—brain cancer	0.00233	0.00429	CcSEcCtD
Methyldopa—Myalgia—Carmustine—brain cancer	0.0023	0.00423	CcSEcCtD
Methyldopa—Vomiting—Procarbazine—brain cancer	0.00224	0.00412	CcSEcCtD
Methyldopa—Cardiac disorder—Etoposide—brain cancer	0.00223	0.0041	CcSEcCtD
Methyldopa—Arthralgia—Temozolomide—brain cancer	0.00222	0.00409	CcSEcCtD
Methyldopa—Myalgia—Temozolomide—brain cancer	0.00222	0.00409	CcSEcCtD
Methyldopa—Rash—Procarbazine—brain cancer	0.00222	0.00409	CcSEcCtD
Methyldopa—Dermatitis—Procarbazine—brain cancer	0.00222	0.00409	CcSEcCtD
Methyldopa—Headache—Procarbazine—brain cancer	0.00221	0.00406	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00221	0.00406	CcSEcCtD
Methyldopa—Oedema—Carmustine—brain cancer	0.0022	0.00406	CcSEcCtD
Methyldopa—Infection—Carmustine—brain cancer	0.00219	0.00403	CcSEcCtD
Methyldopa—ADRA2A—brain—brain cancer	0.00218	0.00493	CbGeAlD
Methyldopa—Angiopathy—Etoposide—brain cancer	0.00218	0.00401	CcSEcCtD
Methyldopa—Mediastinal disorder—Etoposide—brain cancer	0.00216	0.00398	CcSEcCtD
Methyldopa—Thrombocytopenia—Carmustine—brain cancer	0.00216	0.00397	CcSEcCtD
Methyldopa—Body temperature increased—Hydroxyurea—brain cancer	0.00216	0.00397	CcSEcCtD
Methyldopa—Oedema—Temozolomide—brain cancer	0.00213	0.00392	CcSEcCtD
Methyldopa—Infection—Temozolomide—brain cancer	0.00212	0.0039	CcSEcCtD
Methyldopa—Nausea—Procarbazine—brain cancer	0.00209	0.00385	CcSEcCtD
Methyldopa—Nervous system disorder—Temozolomide—brain cancer	0.00209	0.00385	CcSEcCtD
Methyldopa—Thrombocytopenia—Temozolomide—brain cancer	0.00209	0.00384	CcSEcCtD
Methyldopa—Skin disorder—Temozolomide—brain cancer	0.00207	0.00381	CcSEcCtD
Methyldopa—Hypersensitivity—Hydroxyurea—brain cancer	0.00201	0.0037	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Carmustine—brain cancer	0.00201	0.0037	CcSEcCtD
Methyldopa—Paraesthesia—Carmustine—brain cancer	0.00198	0.00364	CcSEcCtD
Methyldopa—Asthenia—Hydroxyurea—brain cancer	0.00196	0.0036	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Temozolomide—brain cancer	0.00194	0.00357	CcSEcCtD
Methyldopa—Paraesthesia—Temozolomide—brain cancer	0.00191	0.00352	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Carmustine—brain cancer	0.0019	0.0035	CcSEcCtD
Methyldopa—Constipation—Carmustine—brain cancer	0.00189	0.00347	CcSEcCtD
Methyldopa—Leukopenia—Etoposide—brain cancer	0.00187	0.00344	CcSEcCtD
Methyldopa—Diarrhoea—Hydroxyurea—brain cancer	0.00187	0.00343	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Temozolomide—brain cancer	0.00184	0.00339	CcSEcCtD
Methyldopa—Constipation—Temozolomide—brain cancer	0.00182	0.00335	CcSEcCtD
Methyldopa—Dizziness—Hydroxyurea—brain cancer	0.0018	0.00332	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00177	0.00325	CcSEcCtD
Methyldopa—Body temperature increased—Carmustine—brain cancer	0.00174	0.00321	CcSEcCtD
Methyldopa—Vomiting—Hydroxyurea—brain cancer	0.00173	0.00319	CcSEcCtD
Methyldopa—Rash—Hydroxyurea—brain cancer	0.00172	0.00316	CcSEcCtD
Methyldopa—Dermatitis—Hydroxyurea—brain cancer	0.00172	0.00316	CcSEcCtD
Methyldopa—Headache—Hydroxyurea—brain cancer	0.00171	0.00314	CcSEcCtD
Methyldopa—Infection—Etoposide—brain cancer	0.00169	0.00312	CcSEcCtD
Methyldopa—Body temperature increased—Temozolomide—brain cancer	0.00168	0.0031	CcSEcCtD
Methyldopa—Thrombocytopenia—Etoposide—brain cancer	0.00167	0.00307	CcSEcCtD
Methyldopa—Skin disorder—Etoposide—brain cancer	0.00166	0.00305	CcSEcCtD
Methyldopa—Hypersensitivity—Carmustine—brain cancer	0.00162	0.00299	CcSEcCtD
Methyldopa—Nausea—Hydroxyurea—brain cancer	0.00162	0.00298	CcSEcCtD
Methyldopa—Asthenia—Carmustine—brain cancer	0.00158	0.00291	CcSEcCtD
Methyldopa—Hypersensitivity—Temozolomide—brain cancer	0.00157	0.00289	CcSEcCtD
Methyldopa—Paraesthesia—Etoposide—brain cancer	0.00153	0.00282	CcSEcCtD
Methyldopa—Asthenia—Temozolomide—brain cancer	0.00153	0.00281	CcSEcCtD
Methyldopa—Diarrhoea—Carmustine—brain cancer	0.00151	0.00278	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—brain cancer	0.00147	0.00271	CcSEcCtD
Methyldopa—Dizziness—Carmustine—brain cancer	0.00146	0.00268	CcSEcCtD
Methyldopa—Constipation—Etoposide—brain cancer	0.00146	0.00268	CcSEcCtD
Methyldopa—Diarrhoea—Temozolomide—brain cancer	0.00146	0.00268	CcSEcCtD
Methyldopa—Dizziness—Temozolomide—brain cancer	0.00141	0.00259	CcSEcCtD
Methyldopa—Vomiting—Carmustine—brain cancer	0.0014	0.00258	CcSEcCtD
Methyldopa—Rash—Carmustine—brain cancer	0.00139	0.00256	CcSEcCtD
Methyldopa—Dermatitis—Carmustine—brain cancer	0.00139	0.00256	CcSEcCtD
Methyldopa—Headache—Carmustine—brain cancer	0.00138	0.00254	CcSEcCtD
Methyldopa—Vomiting—Temozolomide—brain cancer	0.00135	0.00249	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—brain cancer	0.00135	0.00248	CcSEcCtD
Methyldopa—Rash—Temozolomide—brain cancer	0.00134	0.00247	CcSEcCtD
Methyldopa—Dermatitis—Temozolomide—brain cancer	0.00134	0.00247	CcSEcCtD
Methyldopa—Headache—Temozolomide—brain cancer	0.00133	0.00246	CcSEcCtD
Methyldopa—Nausea—Carmustine—brain cancer	0.00131	0.00241	CcSEcCtD
Methyldopa—Nausea—Temozolomide—brain cancer	0.00127	0.00233	CcSEcCtD
Methyldopa—Hypersensitivity—Etoposide—brain cancer	0.00126	0.00231	CcSEcCtD
Methyldopa—Asthenia—Etoposide—brain cancer	0.00122	0.00225	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—brain cancer	0.00117	0.00215	CcSEcCtD
Methyldopa—Dizziness—Etoposide—brain cancer	0.00113	0.00208	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—GLI2—brain cancer	0.00111	0.107	CbGpPWpGaD
Methyldopa—Vomiting—Etoposide—brain cancer	0.00108	0.002	CcSEcCtD
Methyldopa—Rash—Etoposide—brain cancer	0.00108	0.00198	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—brain cancer	0.00107	0.00198	CcSEcCtD
Methyldopa—Headache—Etoposide—brain cancer	0.00107	0.00197	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—GLI1—brain cancer	0.00104	0.1	CbGpPWpGaD
Methyldopa—Nausea—Etoposide—brain cancer	0.00101	0.00186	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—SHH—brain cancer	0.000755	0.0724	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—MPL—brain cancer	0.000491	0.047	CbGpPWpGaD
Methyldopa—DDC—Parkinsons Disease Pathway—CCNE1—brain cancer	0.000398	0.0381	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—HES5—brain cancer	0.00038	0.0364	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—NTRK3—brain cancer	0.00032	0.0307	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—CYP2C9—brain cancer	0.000287	0.0275	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP2C9—brain cancer	0.000283	0.0271	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—STAT3—brain cancer	0.000205	0.0197	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—ESR2—brain cancer	0.000162	0.0155	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—HES1—brain cancer	0.000125	0.012	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MPL—brain cancer	0.000117	0.0113	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—SIRT1—brain cancer	0.000106	0.0102	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000103	0.00985	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—CDK4—brain cancer	8.04e-05	0.0077	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CTNNB1—brain cancer	6.29e-05	0.00603	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MPL—brain cancer	6.05e-05	0.0058	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTCH2—brain cancer	6.04e-05	0.00579	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—S100A10—brain cancer	5.8e-05	0.00556	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—brain cancer	5.54e-05	0.00531	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP2C9—brain cancer	5.53e-05	0.0053	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—OR14C36—brain cancer	5.29e-05	0.00507	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—OR4C12—brain cancer	5.29e-05	0.00507	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TRPC6—brain cancer	5.2e-05	0.00499	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP2C9—brain cancer	4.91e-05	0.0047	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OR14C36—brain cancer	4.81e-05	0.00461	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OR4C12—brain cancer	4.81e-05	0.00461	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TRPC6—brain cancer	4.75e-05	0.00455	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BSG—brain cancer	4.7e-05	0.0045	CbGpPWpGaD
Methyldopa—COMT—Metabolism—BSG—brain cancer	4.17e-05	0.004	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—BSG—brain cancer	4.09e-05	0.00392	CbGpPWpGaD
Methyldopa—DDC—Metabolism—IDH1—brain cancer	4.04e-05	0.00387	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VAV1—brain cancer	3.9e-05	0.00374	CbGpPWpGaD
Methyldopa—COMT—Metabolism—IDH1—brain cancer	3.59e-05	0.00344	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—brain cancer	3.42e-05	0.00328	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ENO2—brain cancer	3.19e-05	0.00306	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SHH—brain cancer	3.11e-05	0.00298	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTCH2—brain cancer	3.1e-05	0.00297	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SMO—brain cancer	2.95e-05	0.00283	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTCH1—brain cancer	2.95e-05	0.00283	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OR14C36—brain cancer	2.84e-05	0.00272	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OR4C12—brain cancer	2.84e-05	0.00272	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ENO2—brain cancer	2.84e-05	0.00272	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TRPC6—brain cancer	2.68e-05	0.00257	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ABR—brain cancer	2.68e-05	0.00257	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	2.47e-05	0.00237	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ABR—brain cancer	2.43e-05	0.00233	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DTX2—brain cancer	2.41e-05	0.00231	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VAV1—brain cancer	2.01e-05	0.00193	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2C9—brain cancer	1.95e-05	0.00187	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTCH2—brain cancer	1.83e-05	0.00175	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES5—brain cancer	1.77e-05	0.0017	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—brain cancer	1.74e-05	0.00167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STRADA—brain cancer	1.72e-05	0.00165	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—TRPC6—brain cancer	1.69e-05	0.00162	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BSG—brain cancer	1.66e-05	0.00159	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SHH—brain cancer	1.6e-05	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—TRPC6—brain cancer	1.54e-05	0.00147	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTCH1—brain cancer	1.51e-05	0.00145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SMO—brain cancer	1.51e-05	0.00145	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—brain cancer	1.48e-05	0.00142	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—brain cancer	1.47e-05	0.0014	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ABR—brain cancer	1.44e-05	0.00138	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—IDH1—brain cancer	1.43e-05	0.00137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLI2—brain cancer	1.39e-05	0.00133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLI1—brain cancer	1.3e-05	0.00125	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—brain cancer	1.3e-05	0.00125	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—brain cancer	1.28e-05	0.00122	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—VAV1—brain cancer	1.27e-05	0.00122	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SUFU—brain cancer	1.24e-05	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GFAP—brain cancer	1.19e-05	0.00114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—VAV1—brain cancer	1.15e-05	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY1—brain cancer	1.13e-05	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO2—brain cancer	1.13e-05	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DLL1—brain cancer	1.11e-05	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SHH—brain cancer	9.43e-06	0.000903	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TRPC6—brain cancer	9.09e-06	0.000871	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—brain cancer	8.97e-06	0.00086	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMO—brain cancer	8.93e-06	0.000857	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTCH1—brain cancer	8.93e-06	0.000857	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—brain cancer	8.06e-06	0.000773	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—brain cancer	7.63e-06	0.000731	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—brain cancer	7.32e-06	0.000702	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH2—brain cancer	7.14e-06	0.000685	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VAV1—brain cancer	6.81e-06	0.000653	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—brain cancer	5.86e-06	0.000561	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—brain cancer	5.76e-06	0.000552	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—brain cancer	5.67e-06	0.000544	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFRA—brain cancer	5.58e-06	0.000535	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—brain cancer	5.41e-06	0.000519	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—brain cancer	5.17e-06	0.000496	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—brain cancer	5.15e-06	0.000494	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS2—brain cancer	4.9e-06	0.000469	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—brain cancer	4.32e-06	0.000414	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—brain cancer	4.32e-06	0.000414	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—brain cancer	3.94e-06	0.000378	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RELA—brain cancer	3.38e-06	0.000324	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—brain cancer	3.36e-06	0.000322	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—brain cancer	3.04e-06	0.000292	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—brain cancer	2.97e-06	0.000284	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNB1—brain cancer	2.94e-06	0.000282	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—brain cancer	2.59e-06	0.000248	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—brain cancer	2.56e-06	0.000245	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—brain cancer	2.38e-06	0.000228	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—brain cancer	2.33e-06	0.000223	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—brain cancer	1.95e-06	0.000187	CbGpPWpGaD
